Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Aug 4, 2026
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced that at its July 29, 2026 general meeting shareholders approved all four resolutions, including a one-for-10,000 reverse stock split of ordinary shares effective July 30, 2026. Concurrently, the ordinary-share-to-ADS ratio changed by the same 10,000 factor, from one ADS per 500,000 ordinary shares to one per 50, so the ADS count is unchanged at 1,029,063 and ADS holders' proportional ownership is not affected; post-reorganization there are 51,453,281 ordinary shares outstanding.
Key figures
- Shares Offered
- 170,150 ordinary shares represented by 3,403 ADSs (registered for resale by selling shareholders)
- Ads ratio new
- 1 ADS per 50 ordinary shares
- Ads ratio prior
- 1 ADS per 500,000 ordinary shares
- Reverse split ratio
- 1:10,000
- Allotment authority gbp
- 25000000
- Reverse split effective date
- 2026-07-30
- Ads closing price aug 3 2026 usd
- 1.42
- Allotment authority valid through
- 2029 annual general meeting
- Post reorganization ads outstanding
- 1029063
- Nominal value per ordinary share gbp
- 0.000001
- Post reorganization ordinary shares outstanding
- 51453281
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.